Latest / Community Health Media
Dr. Rena Callahan & Dr. Aditya Bardia - Integrating T-DXd in HER2+ Breast Cancer: DB11, DB05 & DB09
HER2-positive breast cancer treatment is evolving rapidly. With FDA approvals from DESTINY-Breast11 and DESTINY-Breast05, when should clinicians incorporate trastuzumab deruxtecan (T-DXd) into practice—and how should it be used across early-stage and into metastatic disease?
In this in-depth discussion, Dr. Rena Callahan and Dr. Aditya Bardia explore how these landmark studies are changing treatment decisions today across neoadjuvant, adjuvant, and metastatic settings—including the management of residual disease and the optimization of first-line metastatic care.Key topics discussed:
How…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.